Pressure BioSciences, Inc.

Equities

PBIO

US74112E2081

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets 10:38:34 2024-04-29 am EDT			5-day change	1st Jan Change
0.2253 ^USD	-0.66%		-8.04%	-31.73%

Feb. 15	Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing	CI
Feb. 05	Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call

Pressure BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

April 12, 2023 at 05:01 pm EDT

Pressure BioSciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 1.73 million compared to USD 2 million a year ago. Net loss was USD 16.08 million compared to USD 20.15 million a year ago.

Basic loss per share from continuing operations was USD 1.61 compared to USD 3.42 a year ago. Diluted loss per share from continuing operations was USD 1.61 compared to USD 3.42 a year ago.

Latest news about Pressure BioSciences, Inc.

Pressure BioSciences, Inc. Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing	Feb. 15	CI
Transcript : CBH International LLC, Pressure BioSciences, Inc. - M&A Call	Feb. 05
Pressure BioSciences, Inc. completed the acquisition of CBH International LLC.	Jan. 21	CI
Pressure BioSciences, Inc. Receives Open Order Agreement from West Coast Manufacturing Partner	Jan. 18	CI
Pressure BioSciences, Inc. entered into a definitive agreement to acquire CBH International LLC.	Jan. 10	CI
Pressure BioSciences' BaroFold Platform Expected to Revolutionize Biopharmaceutical Production with Help from New Computational (AI/ML) Technologies	Jan. 04	CI
Pressure BioSciences, Inc. Announces the Publication of Pivotal Scientific Study in the Critical Field of Food Safety	Dec. 12	CI
Pressure BioSciences and Veterans Service Team Launch UltraShear Best-in-Class Nano-CBD Topical Spray - MMA Champ Cat Zingano Now Official VST Ambassador	Dec. 01	CI
Transcript : Pressure BioSciences, Inc., Q3 2023 Earnings Call, Nov 21, 2023	Nov. 21
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Reports Q3 Revenue $413,009	Nov. 21	MT
Pressure BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Pressure Biosciences Announces Exclusive Distribution Agreement with Bioscreen Instruments Pvt Ltd	23-10-18	CI
Pressure BioSciences' Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately	23-09-22	CI
Transcript : Pressure BioSciences, Inc., Q2 2023 Earnings Call, Aug 22, 2023	23-08-22
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q2 Revenue $511,800	23-08-22	MT
Pressure BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Transcript : Pressure BioSciences, Inc. - Special Call	23-08-17
Pressure BioSciences, Inc. Announces UltraShear Nano-CBD Roll-Out Program Enters Rapid Expansion Phase of Distribution and Partnering	23-07-17	CI
Pressure BioSciences, Inc. Announces UltraShear Processed Nano-CBD Topical Spray Distribution Agreement with Premier CA Cannabis Partner Creme de Canna	23-07-10	CI
Pressure BioSciences, Inc. Announces Agreement with Somalab International LLC for Development & Distribution of UltraShear-Enabled Nanoemulsified Health and Wellness Products	23-07-05	CI
Transcript : Pressure BioSciences, Inc. - Special Call	23-06-27
Pressure Biosciences, Inc. Announces Results from Third Round of Consumer Focus Group Testing of THC Nanoemulsion Oral Spray	23-06-27	CI
Pressure BioSciences, Inc. Partners with Veterans Service Team to Offer Exclusive Access for VST Members to a Unique, Custom-Made, UltraShear Nano-CBD & Other Products	23-06-13	CI
Transcript : Pressure BioSciences, Inc., Q1 2023 Earnings Call, May 16, 2023	23-05-16
Earnings Flash (PBIO) PRESSURE BIOSCIENCES Posts Q1 Revenue $740,600	23-05-16	MT

Chart Pressure BioSciences, Inc.

Duration

Period

More charts

Company Profile

Pressure BioSciences, Inc. is engaged in providing broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company's enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. The Company's BaroFold technology platform allows it to enter the bio-pharma contract services and GMP manufacturing equipment sector. It has also developed the scalable and pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be preserved using existing non-thermal technologies.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PRESSURE BIOSCIENCES, INC.	-31.73%	7.63M
ABBOTT LABORATORIES	-2.14%	187B
MEDTRONIC PLC	-1.67%	106B
BECTON, DICKINSON AND COMPANY	-3.83%	66.9B
DEXCOM, INC.	+0.22%	49.45B
CENCORA, INC.	+16.35%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.44%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+1.21%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution